Trial Profile
SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2023
Price :
$35
*
At a glance
- Drugs Landipirdine (Primary)
- Indications Parkinson's disease
- Focus Proof of concept; Therapeutic Use
- Acronyms SYNAPSE
- Sponsors Biotie Therapies Corp.
- 01 Sep 2023 Results assessing safety, tolerability, and efficacy of SYN120 in patients with Parkinson disease dementia (PDD) published in the Parkinsonism and Related Disorders
- 09 Oct 2018 Results assessing impact of Landipirdine on psychiatric symptoms, presented at the 22nd International Congress of Parkinson's Disease and Movement Disorders
- 09 Oct 2018 Primary endpoint has not been met. (Change in Cognitive Drug Research Computerized Cognition Battery (CDR) Continuity of Attention from baseline)